Results From Phase 2b Study On Atrial Fibrillation Agent Reviewed At American Heart Association

ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.

Go to Source

People who read this also read

• AF AWARE Survey Identifies Major Gaps In Reality Vs. Perceptions Of Atrial Fibrillation By Cardiologists And Patients
  Although serious and the most common of heart rhythm disorders, atrial fibrillation (AF) patients are unaware of the risks, complexities and consequences of AF and many doctors find its management to be a clinical and health-economic burden, according to survey results published today in the online ...
• People With Diabetes Are At Higher Risk Of Atrial Fibrillation
  As the U.S. population keeps aging and gaining weight, diabetes is becoming increasingly common. Some research has associated diabetes with the most common kind of chronically irregular heartbeat, called atrial fibrillation , which can raise the risk for stroke and death. But results of past studies...
• Diabetes Patients At Higher Risk Of Developing Atrial Fibrillation – Risk Increases With Diabetes Duration
  Patients with diabetes have a 40% higher risk of developing atrial fibrillation, compared to people who do not have diabetes, according to a study published in the Journal of General Internal Medicine. The study was carried out by Dr. Sarcha Dublin and team of Group Health Research Institute. The sc...
• Detailed, Visual Resource Helps Healthcare Professionals Bridge Gaps In Education, Management Of Atrial Fibrillation
  AF Stat™ - a collaboration of healthcare leaders and organizations working to improve the health and well-being of people affected by atrial fibrillation (AFib) has unveiled the "AFib Educator," a smartphone app and desktop widget to help healthcare practitioners better explain the risks and conseq...
• Dabigatran Etexilate Shows Greater Reductions Than Warfarin In Stroke In Patients With Atrial Fibrillation Across All Stroke Risk Groups
  Data presented at the 59th Annual Scientific Session of the American College of Cardiology have shown greater reductions in stroke in patients with atrial fibrillation (AF) for dabigatran etexilate* compared to the current standard of care, warfarin, irrespective of a patient's risk profile for stro...